Specific biologic effects of intestinal glucagon-like materials. 1973

R A Gutman, and G Fink, and N Voyles, and H Selawry, and J C Penhos, and A Lepp, and L Recant

It has been demonstrated that gastrointestinal extracts contain substances which react immunologically with antibodies prepared to pancreatic glucagon. These extracts have been termed intestinal GLI for glucagon-like immunoreactivity, or enteroglucagon. To determine whether GLI has specific biological effects, studies were designed using the criterion of effect with antiglucagon antibodies. These antibodies did not cross-react with either secretin or pancreozymin. Rat intestinal extracts were prepared and filtered on Sephadex G-50 columns eluted in 0.02 M ammonium carbonate buffer pH 8.8. Two peaks of GLI (I, II) were consistently found, and the in vitro effects of these peaks on two biological systems were tested: (a) immunoreactive insulin (IRI) release by rat pancreas pieces, and (b) free fatty acid (FFA) release and 3',5'-cyclic adenosine monophosphate (cAMP) levels in adipose tissue. Both GLI peaks increased IRI release in the absence of glucose and also enhanced the glucose effects. Antiglucagon antibody suppressed only peak II GLI activity. Both peaks increased FFA release and cAMP levels in adipose tissue. Only peak II GLI activity was suppressed by antibody. These findings support a specific IRI-releasing and lipolytic action for Peak II GLI. Hypotheses are presented concerning the structure and possible physiologic role of peak II GLI.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007422 Intestines The section of the alimentary canal from the STOMACH to the ANAL CANAL. It includes the LARGE INTESTINE and SMALL INTESTINE. Intestine
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D002766 Cholecystokinin A peptide, of about 33 amino acids, secreted by the upper INTESTINAL MUCOSA and also found in the central nervous system. It causes gallbladder contraction, release of pancreatic exocrine (or digestive) enzymes, and affects other gastrointestinal functions. Cholecystokinin may be the mediator of satiety. Pancreozymin,CCK-33,Cholecystokinin 33,Uropancreozymin
D002850 Chromatography, Gel Chromatography on non-ionic gels without regard to the mechanism of solute discrimination. Chromatography, Exclusion,Chromatography, Gel Permeation,Chromatography, Molecular Sieve,Gel Filtration,Gel Filtration Chromatography,Chromatography, Size Exclusion,Exclusion Chromatography,Gel Chromatography,Gel Permeation Chromatography,Molecular Sieve Chromatography,Chromatography, Gel Filtration,Exclusion Chromatography, Size,Filtration Chromatography, Gel,Filtration, Gel,Sieve Chromatography, Molecular,Size Exclusion Chromatography
D005230 Fatty Acids, Nonesterified FATTY ACIDS found in the plasma that are complexed with SERUM ALBUMIN for transport. These fatty acids are not in glycerol ester form. Fatty Acids, Free,Free Fatty Acid,Free Fatty Acids,NEFA,Acid, Free Fatty,Acids, Free Fatty,Acids, Nonesterified Fatty,Fatty Acid, Free,Nonesterified Fatty Acids
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor

Related Publications

R A Gutman, and G Fink, and N Voyles, and H Selawry, and J C Penhos, and A Lepp, and L Recant
January 1999, JPEN. Journal of parenteral and enteral nutrition,
R A Gutman, and G Fink, and N Voyles, and H Selawry, and J C Penhos, and A Lepp, and L Recant
September 1991, Journal of orthopaedic research : official publication of the Orthopaedic Research Society,
R A Gutman, and G Fink, and N Voyles, and H Selawry, and J C Penhos, and A Lepp, and L Recant
January 2008, Microsurgery,
R A Gutman, and G Fink, and N Voyles, and H Selawry, and J C Penhos, and A Lepp, and L Recant
February 1979, Endocrinologia japonica,
R A Gutman, and G Fink, and N Voyles, and H Selawry, and J C Penhos, and A Lepp, and L Recant
April 2009, The Journal of surgical research,
R A Gutman, and G Fink, and N Voyles, and H Selawry, and J C Penhos, and A Lepp, and L Recant
August 2018, The Journal of clinical endocrinology and metabolism,
R A Gutman, and G Fink, and N Voyles, and H Selawry, and J C Penhos, and A Lepp, and L Recant
December 2010, Neurogastroenterology and motility,
R A Gutman, and G Fink, and N Voyles, and H Selawry, and J C Penhos, and A Lepp, and L Recant
October 1981, Life sciences,
R A Gutman, and G Fink, and N Voyles, and H Selawry, and J C Penhos, and A Lepp, and L Recant
January 2014, Pancreas,
R A Gutman, and G Fink, and N Voyles, and H Selawry, and J C Penhos, and A Lepp, and L Recant
September 2002, The Journal of surgical research,
Copied contents to your clipboard!